747 related articles for article (PubMed ID: 31948641)
1. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Bittner VA; Szarek M; Aylward PE; Bhatt DL; Diaz R; Edelberg JM; Fras Z; Goodman SG; Halvorsen S; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Moriarty PM; Moryusef A; Pordy R; Roe MT; Sinnaeve P; Tsimikas S; Vogel R; White HD; Zahger D; Zeiher AM; Steg PG; Schwartz GG;
J Am Coll Cardiol; 2020 Jan; 75(2):133-144. PubMed ID: 31948641
[TBL] [Abstract][Full Text] [Related]
2. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E; Steg PG; Szarek M; Bhatt DL; Bittner VA; Danchin N; Diaz R; Goodman SG; Harrington RA; Jukema JW; Liberopoulos E; Marx N; McGinniss J; Manvelian G; Pordy R; Scemama M; White HD; Zeiher AM; Schwartz GG;
Circulation; 2022 Aug; 146(9):657-672. PubMed ID: 35770629
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG; Szarek M; Bittner VA; Diaz R; Goodman SG; Jukema JW; Landmesser U; López-Jaramillo P; Manvelian G; Pordy R; Scemama M; Sinnaeve PR; White HD; Gabriel Steg P;
J Am Coll Cardiol; 2021 Aug; 78(5):421-433. PubMed ID: 34325831
[TBL] [Abstract][Full Text] [Related]
5. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
Schwartz GG; Gabriel Steg P; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Jukema JW; Kim YU; Li QH; Manvelian G; Pordy R; Sourdille T; White HD; Szarek M;
Circulation; 2021 Mar; 143(11):1109-1122. PubMed ID: 33438437
[TBL] [Abstract][Full Text] [Related]
6. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C;
Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832
[TBL] [Abstract][Full Text] [Related]
7. Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Steg PG; Szarek M; Bhatt DL; Bittner VA; Brégeault MF; Dalby AJ; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Lecorps G; Mahaffey KW; Moryusef A; Ostadal P; Parkhomenko A; Pordy R; Roe MT; Tricoci P; Vogel R; White HD; Zeiher AM; Schwartz GG
Circulation; 2019 Jul; 140(2):103-112. PubMed ID: 31117810
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
Bhatt DL; Briggs AH; Reed SD; Annemans L; Szarek M; Bittner VA; Diaz R; Goodman SG; Harrington RA; Higuchi K; Joulain F; Jukema JW; Li QH; Mahaffey KW; Sanchez RJ; Roe MT; Lopes RD; White HD; Zeiher AM; Schwartz GG; Gabriel Steg P;
J Am Coll Cardiol; 2020 May; 75(18):2297-2308. PubMed ID: 32381160
[TBL] [Abstract][Full Text] [Related]
9. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Szarek M; Bittner VA; Aylward P; Baccara-Dinet M; Bhatt DL; Diaz R; Fras Z; Goodman SG; Halvorsen S; Harrington RA; Jukema JW; Moriarty PM; Pordy R; Ray KK; Sinnaeve P; Tsimikas S; Vogel R; White HD; Zahger D; Zeiher AM; Steg PG; Schwartz GG;
Eur Heart J; 2020 Nov; 41(44):4245-4255. PubMed ID: 33051646
[TBL] [Abstract][Full Text] [Related]
12. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG; Steg PG; Szarek M; Bhatt DL; Bittner VA; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Lecorps G; Mahaffey KW; Moryusef A; Pordy R; Quintero K; Roe MT; Sasiela WJ; Tamby JF; Tricoci P; White HD; Zeiher AM;
N Engl J Med; 2018 Nov; 379(22):2097-2107. PubMed ID: 30403574
[TBL] [Abstract][Full Text] [Related]
13. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK; Colhoun HM; Szarek M; Baccara-Dinet M; Bhatt DL; Bittner VA; Budaj AJ; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Lopes RD; Moryusef A; Murin J; Pordy R; Ristic AD; Roe MT; Tuñón J; White HD; Zeiher AM; Schwartz GG; Steg PG;
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):618-628. PubMed ID: 31272931
[TBL] [Abstract][Full Text] [Related]
14. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
Ray KK; Ginsberg HN; Davidson MH; Pordy R; Bessac L; Minini P; Eckel RH; Cannon CP
Circulation; 2016 Dec; 134(24):1931-1943. PubMed ID: 27777279
[TBL] [Abstract][Full Text] [Related]
15. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial.
Jukema JW; Szarek M; Zijlstra LE; de Silva HA; Bhatt DL; Bittner VA; Diaz R; Edelberg JM; Goodman SG; Hanotin C; Harrington RA; Karpov Y; Moryusef A; Pordy R; Prieto JC; Roe MT; White HD; Zeiher AM; Schwartz GG; Steg PG;
J Am Coll Cardiol; 2019 Sep; 74(9):1167-1176. PubMed ID: 30898609
[TBL] [Abstract][Full Text] [Related]
16. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
[TBL] [Abstract][Full Text] [Related]
17. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ostadal P; Steg PG; Poulouin Y; Bhatt DL; Bittner VA; Chua T; Diaz R; Goodman SG; Huo Y; Jukema JW; Karpov Y; Pordy R; Scemama M; Szarek M; White HD; Schwartz GG;
Lancet Diabetes Endocrinol; 2022 May; 10(5):330-340. PubMed ID: 35378068
[TBL] [Abstract][Full Text] [Related]
18. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests.
Szarek M; Reijnders E; Jukema JW; Bhatt DL; Bittner VA; Diaz R; Fazio S; Garon G; Goodman SG; Harrington RA; Ruhaak LR; Schwertfeger M; Tsimikas S; White HD; Steg PG; Cobbaert C; Schwartz GG;
Circulation; 2024 Jan; 149(3):192-203. PubMed ID: 37632469
[TBL] [Abstract][Full Text] [Related]
19. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.
Goodman SG; Aylward PE; Szarek M; Chumburidze V; Bhatt DL; Bittner VA; Diaz R; Edelberg JM; Hanotin C; Harrington RA; Jukema JW; Kedev S; Letierce A; Moryusef A; Pordy R; Ramos López GA; Roe MT; Viigimaa M; White HD; Zeiher AM; Steg PG; Schwartz GG;
J Am Coll Cardiol; 2019 Sep; 74(9):1177-1186. PubMed ID: 31466614
[TBL] [Abstract][Full Text] [Related]
20. Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.
Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Eckel RH; Cannon CP; Lee LV; Bessac L; Pordy R; Letierce A; Ray KK
J Am Heart Assoc; 2018 Sep; 7(18):e009221. PubMed ID: 30371190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
